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Abstract
Background—Variations in mammography interpretations may have important clinical and
economic implications. To evaluate international variability in mammography interpretation, we
analyzed published reports from community-based screening programs from around the world.
Methods—A total of 32 publications were identified in MEDLINE that fit the study inclusion
criteria. Data abstracted from the publications included features of the population screened,
examination technique, and clinical outcomes, including the percentage of mammograms judged
to be abnormal, positive predictive value of an abnormal mammogram (PPVA), positive predictive
value of a biopsy performed (PPVB), and percentages of breast cancer patients with ductal
carcinoma in situ (DCIS) and minimal disease (DCIS and/or tumor size ≤10 mm). North
American screening programs were compared with those from other countries using meta-
regression analysis. All statistical tests were two-sided.
Results—Wide ranges were noted for the percentage of mammograms judged to be abnormal
(1.2%–15.0%), for PPVA (3.4%–48.7%), for PPVB (5.0%–85.2%), for percentage diagnosed with
DCIS (4.3%–68.1%), and for percentage diagnosed with minimal disease (14.0%–80.6%). The
percentage of mammograms judged to be abnormal were 2–4 percentage points higher in North
American screening programs than they were in programs from other countries, after adjusting for
covariates such as percentage of women who were less than 50 years of age and calendar year in
which the mammogram was performed. The percentage of mammograms judged to be abnormal
had a negative association with PPVA and PPVB (both P <.001) and a positive association with the
frequency of DCIS cases diagnosed (P = .008) and the number of DCIS cases diagnosed per 1000
screens (P = .024); no consistent relationship was observed with the proportion of breast cancer
diagnoses reported as having minimal disease or the number of minimal disease cases diagnosed
per 1000 screens.
Conclusion—North American screening programs appear to interpret a higher percentage of
mammograms as abnormal than programs from other countries without evident benefit in the yield
of cancers detected per 1000 screens, although an increase in DCIS detection was noted.
Substantial intra- and interobserver variability has been noted among radiologists
interpreting screening mammograms in research situations (1–3). This variability is similar
to that seen in other areas of medicine where observation and interpretation are subjective
(4,5). Several studies in the United States (6–8) have suggested that variation in
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mammography interpretation also exists among radiologists in community-based facilities.
One review (6) of U.S. screening programs found that the percentage of screening
mammograms for which additional work-up is recommended (i.e., percentage of
mammograms judged to be abnormal, often referred to as the recall rate) ranged from
approximately 2% to more than 50%, with an average of 11%. Another study (7) found that
the positive predictive value of a biopsy performed (PPVB) (i.e., the percentage of women
who were actually found to have breast cancer among those referred for biopsy following
screening mammography) ranged from 17% for radiologists practicing in the community to
26% for radiologists practicing at an academic center. A recent study by Elmore et al. (8)
reported that radiologists varied widely in their false-positive rates for interpretation of
screening mammograms, even after controlling for patient, radiologist, and testing
characteristics.
Variability in screening mammography interpretations may have important clinical and
economic implications. Although clinicians do not wish to miss breast cancers, it is
important to minimize unnecessary follow-up diagnostic procedures, costs, and patient
anxiety associated with false-positive screening mammograms.
In this article, we compare published data from community-based mammography screening
programs in North America with similar screening programs in other countries to address
two important questions: 1) To what extent is variability in mammographic interpretation in
community-based screening mammography programs observed between programs in North
America and other countries? and 2) Is variability in mammographic interpretation
associated with different intermediate measures of breast cancer outcome (i.e., percentage of
breast cancer cases with ductal carcinoma in situ [DCIS] and/or minimal disease)? Based on
our findings, we discuss possible explanations for variability in mammography
interpretations and of the implications that this variability might have on future research,
health policy, and patient care.
Methods
Search Methods and Selection Criteria
A MEDLINE search identified 227 English and non–English language candidate
publications between January 1, 1985, and June 15, 2002. Search terms included 1)
mammography, 2) mass screening, and 3) biopsy. In addition, the references cited within
these publications were searched for any publications that may fit the study inclusion
criteria. To be included in this study, a publication had to report results of screening
mammography performed in or after 1985. Screening mammograms were defined as
mammograms obtained on women with no known breast-related symptoms or abnormalities
and no known breast cancer at the time of the screen. In addition, at least two of the three
measures of physicians’ interpretation (i.e., percentage of mammograms judged to be
abnormal, positive predictive value of an abnormal mammogram [PPVA], and PPVB) and at
least one of the two intermediate breast cancer outcomes (i.e., percentage of breast cancer
cases with DCIS or percentage with minimal disease) had to be available. For breast cancer
screening programs that had published more than one article, we attempted to select the
most recent data covering the largest geographic area and the largest number of women.
Results from randomized clinical trials and case–control studies were excluded from this
study because data from research settings may have less generalizability to current
community-based practice.
A total of 32 published articles met the study inclusion criteria. Each of these final
publications was reviewed independently by at least two authors (J. G. Elmore, L. Desnick,
and C. Y. Nakano) to determine if it met the study inclusion criteria. When information was
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not clear from the publication, the authors of the article were contacted to obtain that
information (see supplemental information available at
http://jncicancerspectrum.oupjournals.org/jnci/content/vol95issue18/). When disagreements
between the text of an article and the data presented in the tables were noted, we chose to
use the data from the tables. Information on the characteristics of the population screened,
features of the mammogram examination, and outcome of readings were abstracted from
each publication that met the study inclusion criteria.
Characteristics of the Population Screened
Age of the women screened was abstracted from each article because mammography
sensitivity, specificity, and positive predictive value have been found to increase in older
women (9). Each article was also classified as including initial screens only, subsequent
screens only, or mixed screens (i.e., both initial and subsequent). Results from first-time
(e.g., initial) mammographic screening include prevalent cancers, so the percentage of
mammograms judged to be abnormal and cancer rates may be expected to be higher than in
subsequent screens of the same woman (9).
Features of the Mammogram Examination
The number of views taken of each breast was noted (mediolateral oblique and craniocaudal
views versus a single-view mammogram). The use of two-view mammography improves
sensitivity and specificity and reduces the percentage of mammograms judged to be
abnormal (10,11). The year in which the mammograms were performed (not the year of
publication) was also abstracted because possible improvements in the quality of
mammograms over time and secular trends toward an increasing false-positive rate have
been noted in the United States (12).
The mammographic interpretive process in each publication was categorized as involving a
single radiologist versus separate readings by two radiologists, because double reading of
mammograms has been associated with improved accuracy (13,14). If the interpretive
process was not stated explicitly, we relied on the use of the term “radiologist” (i.e.,
singular) in the published literature to imply single-reader interpretation. Although single-
reader interpretation is the standard-of-care in most North American screening programs, in
other countries, interpretation is often performed by two radiologists (15). The actual
method of double reading of mammograms was not stated in most of the publications we
studied, but it presumably included two radiologists interpreting each film independently
(e.g., blinded), with disagreements decided by consensus or by two radiologists reading each
film together.
Outcome of Mammographic Readings
Most published studies during this time period (i.e., between January 1, 1985, and June 15,
2002) did not describe screening mammography program results using standardized
methods (e.g., Breast Imaging Reporting and Data System [BI-RADS] classification) (16).
Instead, most studies used descriptive prose to define the percentage of mammograms
judged to be abnormal and for the measures of accuracy (e.g., PPVs). Because cancer
mortality was not an available outcome in these studies, intermediate outcomes of several
types were used, as defined below.
The percentage of mammograms judged to be abnormal was defined as the percentage of
screening mammograms that the radiologist believed required further diagnostic evaluation,
which is also sometimes referred to as the callback or recall rate. For the purposes of this
study, our definition included short-interval follow-up diagnostic mammogram within 12
months, additional immediate mammographic views, follow-up with a clinician for physical
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examination correlation (i.e., follow-up on an abnormality), ultrasound, and fine-needle
aspiration or core biopsy. This broad definition corresponds to the use of BI-RADS
classifications 0, 3, 4, and 5 indicating the positivity of an initial screening mammogram
(16). Although a short-interval follow-up is not considered to be a recall according to the
American College of Radiology recommendations (16), we included it in our definition
because of the variability of the published reports—that is, some reports included short-
interval follow-up in their definition of the percentage of mammograms judged to be
abnormal, whereas other reports did not or were not clear in their definition.
PPVA was defined as the percentage of women with abnormal screening mammograms (i.e.,
those with a recall) that ultimately received a diagnosis of breast cancer. PPVA is roughly
equivalent to the American College of Radiology PPV1 classification (16). However, as
noted above, we also included short-interval follow-up (i.e., BI-RADS classification 3).
PPVB was defined as the percentage of women undergoing biopsy as a result of an abnormal
screening mammogram who ultimately received a diagnosis of breast cancer. PPVB is
roughly equivalent to the American College of Radiology PPV3 classification. However, it
is important to note that data on biopsy outcomes in the published articles included fine-
needle aspiration, open and core biopsies, and combinations thereof. Because many articles
did not specify the type of biopsy performed, we could not stratify or interpret by biopsy
type.
Few published studies from community-based settings reported breast cancer mortality
results because of the difficulty in tracking patients and the requirements for long-term
follow-up. For these reasons, intermediate endpoints were used to assess the clinical
outcomes of a screening program. Although tumornode–metastasis (TNM) staging was not
available for most articles, the percentage of women with minimal disease at the time of
diagnosis and the percentage of women with DCIS at the time of diagnosis were commonly
noted. Minimal disease was defined as invasive breast cancer that was less than or equal to
10 mm in diameter and/or DCIS at the time of the diagnosis (17).
Statistical Analysis
To model the proportion of mammograms judged to be abnormal in relation to other study
characteristics, we used meta-regression analysis, a form of regression analysis that extends
random effects meta-analysis (18–20). Meta-regression analysis assumes that, after
accounting for within-study variance in the outcome of interest, the remaining between-
study variance can be divided into systematic and random components. The systematic
component is modeled using regression analysis on study-level covariates. Restricted
maximum likelihood was used to estimate the residual random component of the between-
study variance. The within-study variance was specified as p(1 – p)/n, where p = the
proportion of subjects experiencing the outcome of interest in a given study and n = the
number of subjects on which p was based. All meta-regressions were conducted using the
metareg procedure in Stata 7.0 (Stata Corp., College Station, TX). P values were obtained
by dividing the appropriate regression coefficient by its estimated standard error and then
treating the quotient as a standard normal deviate. All statistical tests were two-sided.
Results
We identified 227 candidate published articles from breast cancer screening programs, of
which 32 (13,21–51) met the study inclusion criteria. A description of the patient
populations screened and the mammography techniques used is shown in Table 1. Of the 32
screening programs identified, eight were located in North America (21–28) and 24 were
located in other countries (13,29,52). All of the studies reviewed were based on screening
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mammograms completed between 1985 and 2000 for the screening programs from North
American and between 1987 and 1999 for the screening programs from other countries. The
number of screening mammograms reported among studies ranged from 1813 (41) to 1 495
744 (34). North American programs had a larger percentage of women under age 50 years
compared with programs from other countries. Most North American programs also used
single radiologist interpreters and two views per breast, whereas programs located in other
countries tended to use double readings and one view per breast. Only one North American
screening program (22) provided data on initial screening examination results, whereas 10
programs (31,34,36,37,39–41,46,47,49) from other countries provided such data (data not
shown), perhaps because many programs in other parts of the world were newly established
in their geographic areas.
The percentage of mammograms judged to be abnormal ranged from 5.5% to 15.0% in the
North American programs compared with the range of 1.2%–12.6% in programs from other
countries (Fig. 1 and Table 2). All of the North American programs reported that the
percentage of mammograms judged to be abnormal exceeded 5%, whereas only 10 of 24
programs from other countries reported percentages above this threshold (Table 2). Overall,
the weighted mean percentage of mammograms judged to be abnormal was statistically
significantly higher in North American screening programs than in programs from other
countries (8.4% versus 5.6%, respectively; difference = 2.8%, 95% confidence interval =
0.5% to 5.1%; P = .018).
To determine whether population characteristics and features of the mammogram
examination confounded the difference in the percentage of mammograms judged to be
abnormal between North American screening programs and programs from other countries,
the meta-regression models summarized in Fig. 2 were fitted and adjusted for population
characteristics and features of the mammogram examination. The adjusted difference in the
percentage of mammograms judged to be abnormal by program location ranged between
2.0% and 3.9% across all models. In other words, the percentage of mammograms judged to
be abnormal in North American programs was between 2 and 4 percentage points higher
than it was in programs from other countries, even after adjusting for important study
covariates. Confidence intervals excluded 0 in all models, except in the model that adjusted
for the percentage of women who had a mammogram who were less than 50 years old, for
which the confidence intervals were relatively wide. Because the number of screening
programs was relatively small, no attempt was made to control for more than one other
covariate at a time. Among the program characteristics assessed (Fig. 2), program location
was the most statistically significant predictor of the percentage of mammograms judged to
be abnormal. Once program location was in the meta-regression model, no other program
characteristics added statistically significantly to the model.
The PPVA in North American screening programs ranged from a low of 4.4% in New
Mexico (24) to a high of 12.2% in Idaho (23) (Table 2). In the programs from other
countries, the PPVA ranged from a low of 3.4% in Portugal (46) to a high of 48.7% in The
Netherlands (45). Similarly, the PPVB was lower in North American screening programs,
ranging from 16.9% to 51.8%, than it was in programs from other countries, which ranged
from 5.0% to 85.2%. Every North American screening program except that in North
Carolina (25) had a PPVB less than 40%. In contrast, all but four programs from other
countries (35,36,38,46) for which PPVB could be obtained had a PPVB greater than 40%.
The percentage of cancer cases with DCIS at the time of diagnosis ranged from 4.3% to
68.1% (Table 2). Four of eight of the North American screening programs, but only four of
the 24 programs from other countries, reported more than 20% of cases with DCIS. The
percentage of cases with minimal disease at the time of diagnosis ranged from 30.6% to
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80.6% in North American programs and from 14.0% to 55.7% in programs from other
countries (Table 2).
To evaluate the strength of the association between the percentage of mammograms judged
to be abnormal and the six screening outcomes, the scatter plots shown in Fig. 3 were
constructed. The plotting symbol area for each study is proportional to the number of
screening mammograms in the audit. The percentage of mammograms judged to be
abnormal had a strong negative association with PPVA and PPVB, both of which were
highly statistically significant (P<.001). In contrast, the proportion of mammograms judged
to be abnormal had a strong positive association with the proportion of DCIS cases among
women diagnosed with breast cancer (P = .008) and the number of DCIS cases diagnosed
per 1000 screens (P = .024). However, no consistent association was observed between the
percentage of mammograms judged to be abnormal and either the proportion of breast
cancer diagnoses reported as having minimal disease (P = .21) or the number of breast
cancer cases diagnosed per 1000 screens (P = .48).
Discussion
This study assessed international variability in screening mammography interpretations in
community-based programs. The published data show wide ranges in the percentage of
mammograms judged to be abnormal, with the percentage for North American programs
being 2–4 percentage points higher than that for programs from other countries, even after
adjusting for important covariates, including percentage of women less than 50 years of age
who had a mammogram, calendar year in which mammogram was performed, number of
readers for each examination (i.e., single versus double reading), and number of
mammographic views per breast. The percentage of screening mammograms judged to be
abnormal was negatively associated with the positive predictive value (PPVA, PPVB),
without evident benefit in the yield of cancers detected per 1000 screens; however, an
increase was noted in DCIS detection. This finding suggests that many, if not most, of the
presumptively abnormal mammographic interpretations in screening programs with high
percentages of abnormal mammograms turn out to be false positives.
The impact of wide variability on the percentage of mammograms judged to be abnormal
involves trade-offs between benefits and risks of mammography screening. On one hand, a
low percentage of mammograms judged to be abnormal (i.e., <2%) may reflect decreased
sensitivity and missed breast cancers or delay in diagnosis, potentially resulting in more
advanced disease. On the other hand, a high percentage of mammograms judged to be
abnormal (i.e., >10%) might reflect an increased false-positive rate or ‘over-reading’ of
mammographic films. Indeed, the percentage of mammograms judged to be abnormal can
be shown algebraically (see below) to be a weighted average of the true-positive rate (i.e.,
sensitivity) and the false-positive rate (1 – specificity)—that is, the percentage of
mammograms judged to be abnormal = sensitivity × prevalence + (1 – specificity) × (1 –
prevalence). Because the vast majority of women screened do not have breast cancer, (1 –
prevalance) will normally be much greater than the prevalence. Hence, the percentage of
mammograms judged to be abnormal will depend more on the false-positive rate than on the
true-positive rate.
False-positive mammograms can lead to unnecessary diagnostic evaluations and high
medical costs, anxiety for women receiving follow-up evaluations and even, in rare cases,
morbidity (e.g., infections from biopsies, scars) (12,53). False-positive results do not have a
negative impact on subsequent breast cancer screening behavior (54,55). It is estimated that
50% of women will have at least one false-positive mammogram after 10 screening
examinations (12). In the United States, this false-positive rate translates into a substantial
Elmore et al. Page 6













annual financial burden (12). For example, an additional $750 000 000 might be spent on
diagnostic evaluations each year in the United States if the percentage of mammograms
judged to be abnormal were 10% instead of 5% [an estimated 30 million women are
screened annually at an average cost of $500 per false-positive episode (56)]. Conversely, it
is possible that diagnosing women with earlier stage breast cancer can obtain financial
savings (57). It is important, therefore, to learn how clinical benefit, as well as financial cost
and possible harm, is associated with variability in mammography interpretation.
In this descriptive study, marked heterogeneity between the screening studies was noted.
This finding is to be expected in view of differences in characteristics of the population
screened, features of the mammogram examination, and definitions used (e.g., what
constitutes an abnormal mammogram). Although we attempted to deal with this
heterogeneity in the selection of the studies and we applied statistical tests designed for this
type of meta-analysis, interpretation of a possible difference in mammography interpretation
between North American screening programs and those from other countries must be made
with caution. In addition, only aggregate-level measures of demographic and mammography
characteristics were available, rather than data for individual women. Hence, the
circumstances of data collection (e.g., relying on what is available in the published
literature) weaken any statistical conclusions.
Possible Explanations for the Variability Noted
The question that is implicitly raised by our results is, Why are North American radiologists
calling for further evaluations of so many more women, most of whom turn out to have
false-positive mammograms, than radiologists from other countries? Given the extent of
variability in mammographic interpretation noted in the studies we examined and its
potential clinical importance, it is worthwhile discussing the possible sources of this
variability and the implications that these findings might have on future research and health
policy. The variation in mammographic interpretation noted in the published articles that we
studied is likely due to multiple factors as reviewed below and summarized in Table 3.
Characteristics of the population screened—Screening programs differed
substantially in the basic features of the population screened, such as the number of women
less than 50 years old who had a mammogram. Women in this younger age group have
denser breast tissue and a lower incidence of breast cancer, so the sensitivity of
mammographic screening may be lower, although this conclusion is controversial.
Screening programs with a high percentage of younger women might therefore be expected
to have a higher percentage of mammograms judged to be abnormal and to have more false
positives than programs that limit screening examinations to older women. Because breast
density and breast cancer incidence change gradually by decade, the binary age
classification we used (i.e., <50 versus ≥ 50 years) is imperfect; however, data were not
always reported by decade categories.
Differences in the number of women undergoing their first or initial screening mammogram
within each screening program could also explain some of the variability in the
interpretation of mammograms. The percentage of mammograms judged to be abnormal
generally decreases with subsequent screening examinations because comparison films
establish stability of any abnormalities and because the number of incident cancers in a
screened population should be lower than in a non-screened population (9). It is interesting
that many of the screening programs that had the lowest percentage of mammograms judged
to be abnormal and the highest positive predictive value were pilot projects in European
countries where screening mammograms had previously been limited, so a high rate of
abnormalities in those locations might be expected. In addition, if cancers were being
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routinely missed in these programs because of the low percentage of mammograms judged
to be abnormal, one might also expect more late-stage cancers to become apparent; however,
no association was observed between the percentage of mammograms judged to be
abnormal and the proportion of cancers reported as having minimal disease.
It is possible that the populations screened differ in regard to the presence of breast cancer
risk factors, ethnic groups, presence of known breast cancer symptoms at the time of the
mammogram, and the referral status of the woman; however, data for these variables were
not available.
Features of the mammography examination—The screening studies we examined
covered approximately the same time periods, so mammographic equipment and other
technical issues were probably similar. However, all of the North American screening
programs used two mammographic views per breast, whereas one or two mammographic
views were used for programs from other countries. In addition, double reading of films was
more common in screening programs from other countries than it was in programs from
North America. Unfortunately, the published articles did not generally describe the specific
details regarding how double reading was performed (i.e., two independent blind
interpretations versus consensus interpretation). The differences noted between North
American programs and programs from other countries persisted after adjustment for
calendar year, number of views per breast, and use of single versus double readings.
Features of physicians interpreting the mammogram—Previous research has
suggested a positive correlation between a physician’s experience and accuracy of
mammography interpretations (8,58–60), although definitions of experience vary and not all
research has shown a statistically significant association (61,62). In addition, whether a
physician’s personal comfort with ambiguity influences clinical decision-making is an
important but understudied area of research (63). It is possible that physicians who are
uncomfortable with ambiguity interpret a higher percentage of mammograms as abnormal.
Individual physicians have different thresholds for labeling mammograms as abnormal (59);
decision-making aids may help in adjusting the thresholds of selected physicians (64–67).
Features of the health care system—Malpractice concerns may also be contributing
to the high percentage of mammograms judged to be abnormal in some screening programs.
For example, physicians in North America might be reluctant to label a mammogram as
normal, thus leading to higher percentages of mammograms being judged as abnormal. This
higher percentage of mammograms judged to be abnormal would probably lead to more
false-positive mammograms and perhaps more true-positive mammograms with better
sensitivity. It is interesting that malpractice concerns have been shown to affect physicians’
ordering of tests and procedures (68–75). Failure or delay in cancer diagnosis is the most
frequent allegation in medical malpractice claims in the United States (76), with issues
related to breast cancer, particularly delay in diagnosis, being the most common cause of
malpractice claims for all specialties (77). Malpractice concerns are on physicians’ minds,
and some physicians believe that these concerns influence their clinical practice in a variety
of ways, including referring more patients to other physicians and increasing the use of tests
and procedures (68–70,73,77–80). In academic and public screening programs, there is a
possible buffer against malpractice concerns in that physicians are rarely responsible for
their own malpractice insurance or defense in litigation.
Financial incentives inherent to the health care system can also affect physicians’ use of
health care resources (81–83). Physicians in nonprofit mammography programs might differ
in their practice patterns compared with physicians who interpret both screening and
diagnostic mammograms with an incentive plan for high volume. In addition, academic and
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public screening programs might be isolated from the confounding issue of benefiting
financially from additional diagnostic procedures that may follow an abnormal screening
mammogram.
Some screening programs use specialized radiologists and have stated goals to develop high-
quality screening programs that minimize false-positive results (11,22,41). These specialized
programs monitor outcomes through quality control and self-auditing procedures. Programs
that combine clinical breast examination with screening mammography may have higher
biopsy rates because of abnormalities noted on the clinical examination and not necessarily
on the mammography examination. In contrast, smaller, community-based screening
programs may not have access to specialized radiologists.
Finally, national policy regarding desired goals for the percentage of screening
mammograms judged to be abnormal varies (84,85) (Table 4). It is possible that physicians
interpreting mammograms may, to some degree, simply be responding to those goals.
Screening programs may also be using different methods for defining the percentage of
mammograms judged to be abnormal and for calculating cancer outcomes. For example,
some screening programs categorize short-term follow-up as a positive mammogram, which
will elevate the false-positive rate. In addition, some European countries used fine-needle
biopsies earlier than they were routinely used in the United States. The screening programs
from these European countries do not consider fine-needle aspiration a biopsy; however,
they use the aspiration information to decide if an excisional biopsy is warranted, which
could well elevate the reported PPVB for these programs.
In conclusion, substantial variation exists among published reports of community-based
screening mammography programs. The percentage of mammograms judged to be abnormal
in North American programs was 2–4 percentage points higher than it was in programs from
other countries without evident benefit in the yield of cancers detected per 1000 women
screened, although an increase was noted in DCIS detection. Across all screening programs,
the percentage of mammograms judged to be abnormal was inversely associated with
positive predictive value (both PPVA and PPVB). Although some variability might be
explained by differences in patient populations and technique of mammography
examinations, variability may also be due to differences in physicians’ interpretations and in
features of health care systems.
The mammography screening programs described in this article are heterogeneous both in
the methods of auditing their practice and in factors that may affect the interpretation of
results. Currently, it is not possible to determine which features may be most responsible for
the variability. To address this problem, we recommend standardized reporting of
mammography data in the literature, with results stratified for patient characteristics and
features of the examination and data on both process and outcome. We also endorse the new
international standards for reporting diagnostic tests evaluation (86,87), which will improve
the quality of reporting methods and results. In addition, linkage of screening programs to
tumor registries, as is currently being performed in the United States by the Breast Cancer
Surveillance Consortium (88), is critical to obtaining outcome data that go beyond
intermediary endpoints. Outcome data on breast cancer–specific mortality would be the best
comparison but were not available in the published literature. Finally, a better understanding
of the sources of variability in mammography may lead to more effective screening
programs that have a lower percentage of mammograms judged as abnormal without
substantially lowering the cancer detection rate.
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Percentage of mammograms judged to be abnormal from published studies by screening
program location. North American screening programs (n = 8) are shown as open squares,
and programs from other countries (n = 24) are shown as open circles. The weighted mean
percentage of mammograms judged to be abnormal was statistically significantly higher in
North American programs than it was in programs from other countries (8.4% versus 5.6%;
difference in weighted mean percentage = 2.8%, 95% confidence interval = 0.5% to 5.1%; P
= .018).
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Differences in the percentage of mammograms judged to be abnormal between North
American screening programs and programs from other countries, after adjustment for
patient population and program characteristics. Differences in the percentages were
calculated as the percentage in North American programs minus the percentage in programs
from other countries. The difference in the percentage of mammograms judged to be
abnormal between North American screening programs and programs from other counties
remained between 2.0% and 3.9%, even after adjustment for the percentage of women less
than 50 years old, reported calendar year in which the mammogram was performed, single
or double mammography readers, and number of mammography views per breast.
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Study-level (i.e., at the individual publication level) association of the percentage of
mammograms judged to be abnormal with the positive predictive value of an abnormal
mammogram (PPVA) (A), the positive predictive value of a biopsy performed (PPVB) (B),
the proportion of cancer cases diagnosed with ductal carcinoma in situ (DCIS) (C), the
proportion of cancer cases diagnosed with minimal disease (DCIS and/or tumor size ≤ 10
mm) (D), the number of cancer cases diagnosed per 1000 screening mammograms (E), and
the number of DCIS cases diagnosed per 1000 screening mammograms (F). North American
screening studies are shown as open squares, and screening studies from other countries are
shown as open circles. Symbol area for each study is proportional to the number of
screening mammograms performed.
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Table 3
Possible explanations for the variability noted among published studies of screening mammography
Characteristics of the population screened
   • Age (e.g., percentage of women <50 years of age)
   • Initial versus subsequent screening examination
   • Presence of risk factors for breast cancer
   • Presence of breast symptoms
   • Self-referral versus physician referral
Features of the mammography examination
   • Equipment type and year
   • One or two views of each breast
   • Single or double readings
   • Technician training
Features of physicians interpreting the mammogram
   • Experience of the physician
   • Level of personal comfort with ambiguity
   • Individual thresholds to label film as abnormal
Features of the health care system
   • Malpractice concerns
   • Financial incentives
   • Private versus academic/public programs
   • Different stated goals for the percentage of mammograms judged
     abnormal and positive predictive value
   • Quality control and auditing procedures
   • Variability of definitions used to calculate outcomes
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Table 4
Stated goals for the percentage of screening mammograms judged to be abnormal and the positive predictive
value of a biopsy done (PPVB)
Organization (Ref.) Stated goals
% of mammograms judged
to be abnormal % PPVB
Agency for Health Care Policy and Research (United States) (85) General ≤10 25–40
Europe Against Cancer Programme*(84) Acceptable levels <7 >34
Europe Against Cancer Programme*(84) Desirable levels <5 >50
*
For women aged 50–64 years at their initial screen.
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